Payment overview · 2025
General Payments
$163.12
3 reported records · 2 companies
Healthcare provider profile · identity verified
Janet M Dabson, MD
Allopathic & Osteopathic Physicians|Family Medicine · JANESVILLE, WI · NPI 1083797716
Verified facts
What the public records show
CMS Open Payments records show Janet M Dabson, MD received $163.12 in general payments during 2025 across 3 reported records.
Dexcom, Inc. accounted for 76.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $124.99 | 76.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.13 | 23.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $163.12 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.13 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 818 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 637 | 141 |
| Omeprazole | Omeprazole | 546 | 134 |
| Losartan Potassium | Losartan Potassium | 453 | 114 |
| Lisinopril | Lisinopril | 318 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 69 |
| Metformin Hcl | Metformin Hcl | 308 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 304 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 50 |
| Sertraline Hcl | Sertraline Hcl | 178 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 169 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 38 |
| Gabapentin | Gabapentin | 153 | 43 |
| Simvastatin | Simvastatin | 153 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 36 |
| Ozempic | Semaglutide | 141 | 31 |
| Furosemide | Furosemide | 133 | 42 |
| Bupropion Xl | Bupropion Hcl | 132 | 33 |
| Carvedilol | Carvedilol | 131 | 30 |
| Potassium Chloride | Potassium Chloride | 131 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 36 |
| Atenolol | Atenolol | 122 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 39 |
| Metformin Hcl Er | Metformin Hcl | 113 | 28 |
| Azithromycin | Azithromycin | 102 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 25 |
| Eliquis | Apixaban | 92 | 18 |
| Trazodone Hcl | Trazodone Hcl | 88 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 23 |
| Allopurinol | Allopurinol | 84 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 79 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 14 |
| Famotidine | Famotidine | 78 | 20 |
| Alendronate Sodium | Alendronate Sodium | 75 | 21 |
| Buspirone Hcl | Buspirone Hcl | 72 | 21 |
| Montelukast Sodium | Montelukast Sodium | 70 | 23 |
| Prednisone | Prednisone | 70 | 47 |
| Januvia | Sitagliptin Phosphate | 67 | suppressed |
| Ezetimibe | Ezetimibe | 66 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 19 |
| Lovastatin | Lovastatin | 60 | 11 |
| Cefdinir | Cefdinir | 59 | 38 |
| Meloxicam | Meloxicam | 55 | 16 |
| Trulicity | Dulaglutide | 51 | 11 |
| Gemfibrozil | Gemfibrozil | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 13 |
| Bupropion Hcl | Bupropion Hcl | 47 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 46 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 14 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Glipizide | Glipizide | 42 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 12 |
| Tramadol Hcl | Tramadol Hcl | 40 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Estradiol | Estradiol | 39 | 15 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 22 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 27 |
| Jardiance | Empagliflozin | 33 | suppressed |
| Acyclovir | Acyclovir | 31 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 11 |
| Calcitriol | Calcitriol | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Trimethoprim | Trimethoprim | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $163.12 · 3 records | Dexcom, Inc. | DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Ozempic | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error